Key Highlights

  • Karyopharm Therapeutics (NASDAQ:KPTI) is quoted at USD 0.0311, down 22.25% pre-market on November 10, 2026, after its November 2 Chapter 11 filing, with Nasdaq trading suspended from November 11.
  • Jin Medical International (NASDAQ:ZJYL) is indicated at USD 3.25, down 17.7% from a calculated prior close of USD 3.95, giving back a 17.6% gain from Monday with no catalyst identified in published coverage.
  • Adagio Medical Holdings (NASDAQ:ADGM) is priced at USD 1.62, down 15.62%, on Volume of about 1.10 million shares, roughly 7.5 times its 147,310 average (calculated), with no confirmed catalyst.
  • Lakewood-Amedex (NASDAQ:LABT) is down 11% at USD 0.372 and Bluejay Diagnostics is down 9.24% at USD 2.26, both with no catalyst identified in published coverage dated November 9 or 10.

Karyopharm Therapeutics (NASDAQ:KPTI): Down 22.25% Pre-Market on Chapter 11 and Delisting

Karyopharm Therapeutics (NASDAQ:KPTI) is indicated at USD 0.0311 pre-market, 22.25% under a calculated USD 0.0400 prior close. The driver is the Bankruptcy process, not fresh Tuesday news: the company entered Chapter 11 on November 2, 2026 with a USD 55 million bankruptcy loan, and Ayrmid is the lead bidder in a court-supervised sale. Nasdaq issued a delisting notice on November 4, trading is suspended from November 11, and OTC quotes are expected under KPTIQ. The plan provides that common stockholders receive nothing, following a fall of 83% to USD 0.11 on November 2. In general, remaining shares often trade on speculation, and funds that cannot hold Delisted names may be forced sellers. Published data from October 22 showed 22.68 million shares, total Debt of USD 328.53 million and short interest of 26.70%. The value at this quote is about USD 0.7 million, calculated. Holders of Karyopharm Therapeutics (NASDAQ:KPTI) face a likely total loss.

Jin Medical International (NASDAQ:ZJYL): Down 17.7% Pre-Market With No Catalyst Identified

Jin Medical International (NASDAQ:ZJYL) is indicated at USD 3.25 pre-market, down 17.7% or USD 0.70 from a calculated USD 3.95 prior close. Monday's gain of USD 0.59, or 17.6%, means the prior session started near USD 3.36, so the quote wipes out the entire rally. Published coverage dated November 9 or 10, 2026 identifies no catalyst. Generally, thinly traded small caps often reverse sharp one-day gains without any news. The company makes wheelchairs and oxygen concentrators from Changzhou, China. Market Value was USD 30.92 million on 7,827,355 shares, or about USD 25.44 million at this quote, calculated. Revenue is USD 19.73 million, giving about 1.29 times sales, calculated, with a Debt-to-Equity Ratio of 0.85. The 52-week range is USD 1.53 to USD 5.68. A 1-for-20 share combination left a small float, and a handful of trades can move Jin Medical International (NASDAQ:ZJYL).

Adagio Medical Holdings (NASDAQ:ADGM): Down 15.62% Pre-Market With No Catalyst Confirmed

Adagio Medical Holdings (NASDAQ:ADGM) is indicated at USD 1.62 pre-market, 15.62% under a calculated USD 1.92 prior close, a fall of USD 0.30. Published coverage confirms no catalyst. Background items include a strategic review announced around September 23, 2026 and an October 2026 vote approving a reverse split at any ratio from 1-for-10 to 1-for-500. In general, prices often drift lower after a reverse split, and a strategic review can end in a sale, merger, financing or wind-down. The 52-week range of USD 1.50 to USD 50.70 hints at a 1-for-30 split in the price history, but that ratio is inferred, not confirmed. If it applies, the 22.21 million shares become about 0.74 million and the value at this quote is roughly USD 1.2 million, unverified. The quote page shows USD 57.88 million, which does not reconcile. Results are estimated for November 11, and trailing net loss is USD 27.14 million for Adagio Medical Holdings (NASDAQ:ADGM).

Lakewood-Amedex (NASDAQ:LABT): Down 11% Pre-Market With No Catalyst Identified

Lakewood-Amedex (NASDAQ:LABT) was indicated at USD 0.372 pre-market, 11% below a Monday close of USD 0.4180, which had climbed 8.21% from USD 0.3863. Neither a company release nor a filing dated November 9 or 10, 2026 was identified, so the cause is not established. Nano-cap biotechs tend to move on financing, minimum bid notices, trial timing or fading momentum after a one-day rally. Market value was USD 990.53 thousand at the November 9 close, against USD 120.54 million on April 23, 2026, a fall of 99.18%. Enterprise value was negative USD 3.49 million, and the implied share count of about 2.37 million is calculated, not confirmed in a filing. The lead asset, Nu-3, a topical treatment for infected diabetic foot ulcers, is planned for Phase 2a. Cash, volume and the 52-week range were not available, and dilution is the main risk for Lakewood-Amedex (NASDAQ:LABT).

Bluejay Diagnostics (NASDAQ:BJDX): Down 9.24% Pre-Market With No Catalyst Identified

Bluejay Diagnostics (NASDAQ:BJDX) is indicated at USD 2.26 pre-market, 9.24% below a calculated USD 2.49 prior close, a drop of about USD 0.23. Neither a company release nor a filing dated November 9 or 10, 2026 was identified. The latest confirmed event is a 1-for-4 reverse split effective November 3, which reduced shares outstanding from about 4.5 million to about 1.1 million. Generally, a split leaves the value of a holding unchanged, but stocks can drift lower afterwards when holders sell or new financing is expected. At 1.1 million shares the calculated market value is near USD 2.5 million. The quote sits USD 1.26 above the USD 1.00 Nasdaq minimum bid, and the pre-split equivalent is about USD 0.565, calculated. Quarterly results were expected on November 6, but no figures were retrieved. Average volume, cash and the 52-week range were not verified, and a base this small leaves Bluejay Diagnostics (NASDAQ:BJDX) open to dilution.

Where Things Stand

The top healthcare pre-market loser on Tuesday is Karyopharm Therapeutics (NASDAQ:KPTI) at 22.25%, the only name with a clear catalyst: Chapter 11 and a Nasdaq suspension from November 11, 2026. The common thread is tiny market value and thin trading, often after a reverse split or a sharp rally. Jin Medical International (NASDAQ:ZJYL) gave back a Monday gain. Moves in thinly traded names can reverse at the open, since few shares trade and spreads are wide. These lists rely on a pre-market screener snapshot from November 10, 2026.